199 related articles for article (PubMed ID: 30196795)
1. Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature.
Rujirachun P; Junyavoraluk A; Owattanapanich W; Suvannarerg V; Sirinvaravong S
J Med Case Rep; 2018 Sep; 12(1):257. PubMed ID: 30196795
[TBL] [Abstract][Full Text] [Related]
2. Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Miyoshi N; Tanaka H; Ito T; Katayama Y; Niimi H; Hyodo H; Kimura A
Int J Hematol; 2005 Nov; 82(4):333-7. PubMed ID: 16298826
[TBL] [Abstract][Full Text] [Related]
3. [Hypercalcemia associated with blast crisis of chronic myeloid leukemia].
Murata T; Motomura S; Harano H; Kanamori H; Miyasita H; Ogawa K; Ookubo T
Rinsho Ketsueki; 1990 Feb; 31(2):177-82. PubMed ID: 2184269
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia associated with osteolytic lesions in the extramedullary blastic crisis of chronic myelogenous leukemia: report of a case.
Kubota K; Yanagisawa T; Kurabayashi H; Ono K; Shirakura T; Nagashima K; Yatabe H; Nakazato Y
Blut; 1989 Nov; 59(5):458-9. PubMed ID: 2819252
[TBL] [Abstract][Full Text] [Related]
5. [Hypercalcemia mediated by parathyroid hormone-related protein in the blastic phase of chronic myelogenous leukemia].
Kakihana K; Mizuchi D; Yamaguchi M; Sakashita C; Fukuda T; Yamamoto K; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2002 Feb; 43(2):102-6. PubMed ID: 11925871
[TBL] [Abstract][Full Text] [Related]
6. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein.
Seymour JF; Grill V; Martin TJ; Lee N; Firkin F
Leukemia; 1993 Oct; 7(10):1672-5. PubMed ID: 8412332
[TBL] [Abstract][Full Text] [Related]
7. Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.
Toro-Tobón D; Agosto S; Ahmadi S; Koops M; Bruder JM
Am J Case Rep; 2017 Feb; 18():203-207. PubMed ID: 28239141
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
9. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Maschan A; Novichkova G; Miakova N; Persiantseva M
Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia.
Nadal E; Cervantes F; Rosiñol L; Talarn C; Montserrat E
Leuk Lymphoma; 2001 Mar; 41(1-2):203-6. PubMed ID: 11342375
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
12. Pathobiology of lymphoid and myeloid blast crisis and management issues.
Ilaria RL
Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
[TBL] [Abstract][Full Text] [Related]
13. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
[TBL] [Abstract][Full Text] [Related]
14. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Voglová J; Maisnar V; Beránek M; Chrobák L
Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Liu NS; O'Brien S
Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
[TBL] [Abstract][Full Text] [Related]
17. Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.
Takebayashi K; Sonoda H; Shimizu T; Ohta H; Minamiguchi H; Ishida M; Mekata E; Endo Y; Tani T; Tani M
World J Surg Oncol; 2016 Apr; 14():116. PubMed ID: 27094880
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
20. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
